ALTSTATION.IO

Boston Scientific Corporation (BSX) Stock Analysis

By Nova Skye | AltStation.io | Updated November 07, 2026

Price

$42.94

Change

-3.82%

Market Cap

$62.23B

Avg Volume

19.9M

Company Overview

Boston Scientific Corporation is a Marlborough, Massachusetts-based medical device manufacturer operating in the healthcare sector since its incorporation in 1979. The company designs, builds, and sells specialized interventional hardware directly to hospitals, outpatient clinics, and surgical specialists worldwide. Its business is split across two core operating segments: MedSurg and Cardiovascular. The product lineup spans critical therapeutic areas, from single-use SpyGlass scopes and urological lasers to WATCHMAN FLX cardiac implants and spinal cord stimulator systems.

Boston Scientific holds a dominant market position across several high-barrier interventional categories rather than functioning as a broad generalist. Its competitive edge relies on proprietary clinical hardware like left atrial appendage closure implants and single-use duodenoscopes that solve hospital infection risks. The primary threat to its business comes from rival medical device giants competing directly for cath-lab shelf space and procedure volume. Maintaining leadership requires heavy capital deployment into clinical trials and strict patent defense across every product line.

Operationally, the company is compounding its footprint by driving adoption in less-invasive cardiac therapies, peripheral vascular treatments, and neuromodulation for chronic pain. Its two-segment portfolio provides strong structural balance, pairing high-volume consumables like stents and catheters with high-value implantable defibrillators and deep brain stimulation hardware. Rather than pivoting away from its core, Boston Scientific is doubling down on specialized devices that shorten procedure times and reduce hospital stays. BSX stands as a focused medical device powerhouse with entrenched global distribution and no unnecessary conglomerate baggage.

Key Financials

Market Cap

$62.23B

Revenue

$21.07B

EBITDA

$5.57B

Gross Margin

68.0%

Profit Margin

16.6%

Revenue Growth

1.4%

Total Cash

$609.00M

Total Debt

$11.95B

Free Cash Flow

$2.49B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

18.12

Forward P/E

13.71

Beta

0.58

52-Week High

$105.65

52-Week Low

$39.57

EPS

$2.37

50-Day Avg

$44.41

200-Day Avg

$55.60

Price/Book

2.43

Technical Analysis

BSX trades at $42.94, just 5% of the way from its 52-week low of $39.57 to its high of $105.65. The stock is 59.54% below that high and only 8.04% above the low, confirming a deeply damaged 52-week trend. Price sits 3.31% below the 20-day moving average of $44.21, while momentum is 1.83% over five trading days and just 0.05% over 20 days. Near-term support is $41.58, with resistance at $46.01. A break below $41.58 would put the 52-week low back in focus, while clearing $46.01 would be the first meaningful sign of technical improvement.

Recent News and Developments

Blackstone commits up to $455 million to VITALYST heart pump

Blackstone Life Sciences announced a $455 million collaboration to co-fund Boston Scientific’s VITALYST heart-pump program. The device is being developed to improve blood flow in patients with acute myocardial infarction cardiogenic shock. Source: Blackstone

WATCHMAN FLX Pro trial meets primary endpoints

Boston Scientific said both single-drug regimens in its 1,857-patient SIMPLAAFY trial were noninferior to dual antiplatelet therapy at six months. Ischemic stroke rates were 0.7%, while device-related clotting was 0.9% with reduced-dose NOAC versus 3.4% with dual antiplatelet therapy. Source: Boston Scientific

Analysts split as Citi cuts its BSX target

Citi maintained a Hold rating and cut its price target from $48 to $44 on November 2, while Canaccord Genuity maintained Buy with a $48 target on November 4. J.P. Morgan and Argus Research also maintained Hold ratings on November 3. Source: Stock Analysis

Market Sentiment and Analyst Recommendations

Bull Case

BSX generates $21.07 billion in revenue and carries a P/E of 18.12, which is not excessive if the company can improve its growth rate. The $455 million Blackstone collaboration helps fund the VITALYST heart-pump program, reducing the amount Boston Scientific must carry alone. The 1,857-patient SIMPLAAFY trial also delivered a positive result, with both single-drug regimens meeting the primary noninferiority endpoints at six months. Ischemic stroke rates were 0.7%, and device-related clotting was 0.9% with reduced-dose NOAC versus 3.4% with dual antiplatelet therapy. Analysts remain broadly positive, with a buy recommendation based on 28 analysts and an average target of $49.60. That target sits $6.66 above the current $42.94 price, giving buyers a clear potential upside case if sentiment stabilizes.

Bear Case

Revenue growth is only 1.4%, which is weak for a company expected to justify a buy consensus. The balance sheet is another concern: BSX holds $609 million in cash against $11.95 billion in debt. The stock is 59.54% below its 52-week high, and that scale of decline signals more than routine volatility. Price remains 3.31% below the 20-day moving average, while 20-day momentum is nearly flat at 0.05%. Analysts are also divided, with Citi cutting its target from $48 to $44 on November 2 and maintaining Hold. J.P. Morgan and Argus Research maintained Hold ratings on November 3, showing that the 28-analyst buy recommendation is not unanimous. The bear case is simple: slow growth, heavy debt and a broken chart could keep BSX depressed even with positive clinical data.

What to Watch

The first technical test is whether BSX can hold the $41.58 near-term support level. A break below it would leave the stock close to its $39.57 52-week low, while a move above $46.01 resistance would improve the near-term setup. Investors should also track whether the price can reclaim its $44.21 20-day moving average. Clinical follow-through from the WATCHMAN FLX Pro SIMPLAAFY trial matters after the November 2 report showed a 0.7% ischemic stroke rate and 0.9% device-related clotting with reduced-dose NOAC. Progress on the VITALYST program should be monitored closely because Blackstone has committed up to $455 million to its development. The next quarter also needs to show whether revenue growth can move above the current 1.4% rate. Analyst revisions will be important after Citi moved to a $44 target while Canaccord Genuity maintained Buy with a $48 target on November 4.

Analyst Consensus

BUY

Based on 28 analyst opinions

Low Target

$41.00

Mean Target

$49.60

High Target

$60.00

Earnings and Financial Data

Sector

Healthcare

Industry

Medical Devices

Employees

59,000

Earnings & Dividends

Next Earnings

Oct 28, 2026

EPS (Trailing)

$2.37

Dividend Yield

None

Payout Ratio

Frequently Asked Questions

Is BSX a good stock to buy?

BSX has a buy recommendation from 28 analysts, but the stock trades below its 20-day moving average and only 5% above the bottom of its 52-week range. The takeaway is that analyst sentiment is positive, but the technical trend remains weak.

What is the analyst price target for BSX?

The average analyst target is $49.60, with estimates ranging from $41.00 to $60.00. The takeaway is that the consensus target is above the current $42.94 price, but the lowest target is below it.

How far is BSX below its 52-week high?

BSX is 59.54% below its 52-week high of $105.65. The takeaway is that the stock has suffered a major decline and has not recovered its long-term range.

What are the support and resistance levels for BSX?

Near-term support is $41.58, based on the 30-day low, and near-term resistance is $46.01, based on the 30-day high. The takeaway is that these are the key levels defining the current trading range.

Is BSX financially strong?

Boston Scientific reports $21.07 billion in revenue, $609 million in cash and $11.95 billion in total debt. The takeaway is that the company has substantial revenue, but debt is much larger than its cash position.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated November 07, 2026.